hungrywing
Full Member
Thanks for sharing that. Really enjoyed that article, mind blowingly clever.
You're welcome. I agree it was a nice read.
Thanks for sharing that. Really enjoyed that article, mind blowingly clever.
These then dutifully start producing SARS-CoV-2 Spike proteins in large enough quantities that our immune system springs into action. Confronted with Spike proteins, and tell-tale signs that cells have been taken over, our immune system develops a powerful response against multiple aspects of the Spike protein AND the production process.
The bolded bit suggests that while the mRNA vaccines aren't sterilising they do produce a response not only to the spike protein but also one that attacks the process that produces more virus in the cells. This must surely reduce the transmissibility of the virus?
Antibodies don’t enter cells.
It could be they kill infected cells to stop them from producing more viral proteins?I know. So do you think the article got it wrong? Or am I misinterpreting the quote? Both quiet possible.
A lot of big talk from government in hope of giving the vaccine to millions within a month and essentially going back to some sort of normal in Feb.
Why do they do this everytime
One thing they never run out of is bullshit.
The production and roll out of covid vaccines is a stunning achievement. So why not sell that for what it is rather than polite it with political idiocy?
I know. So do you think the article got it wrong? Or am I misinterpreting the quote? Both quiet possible.
Isn't it a reference to the body destroying both the spikes and the cells that have been pressganged by the vaccine into making spikes?I know. So do you think the article got it wrong? Or am I misinterpreting the quote? Both quiet possible.
That's a fascinating article. I've obviously no idea how accurate it (or the analogies in it) are, but it does seem to help me make sense of other things I've read about how they made them.
Hope the data arrives soon to back up this claim from the CEO of AZ. Maybe a sign of good news to come on the Oxford vaccine.
Hope the data arrives soon to back up this claim from the CEO of AZ. Maybe a sign of good news to come on the Oxford vaccine.
It’s going to be approved on the 29th apparently with jabbing the first week of January. In Wales we’ve finally agreed a monetary package to entice GPs to actually chip in during the biggest national crisis since the Second World War and administer a bit of it. Why it’s all been left to the NHS to undertake the vaccination of millions using the existing registered staff pool that’s already not enough to deal with hospitals being overwhelmed, field hospitals which we can’t staff now opening and thousands off sick/isolating is a fecking shambles. “Unlimited” workforce the government are saying we have. Absolute arses.Hope this is true & the efficacy % applies for all age groups. Would be huge with the benefits of the cost & effort required to store the vaccine.
Thanks for this - interesting readingInteresting analysis of what happened in the early Oxford/AZ trials, and that "half dose" thing.
https://mobile.reuters.com/article/amp/idUSKBN28Y0XU?__twitter_impression=true
Basically says that before AZ stepped in as partners, the Oxford team didn't really have the experience to ramp up from lab scale production to full clinical trial production. As a result they used the wrong test methodology to analyse the first batch of manufactured product (coming from an Italian sub-contractor).
AKA - the manufacturer knew how to test what it was manufacturing, the research team didn't.
Looks like AZ are trying to pick up the PR pieces, as well as running/rerunning the trials now. It would be great news if they have managed to get enough data from their global (AZ standardised) trials to produce some convincing trials results.
Hope the data arrives soon to back up this claim from the CEO of AZ. Maybe a sign of good news to come on the Oxford vaccine.
Interesting analysis of what happened in the early Oxford/AZ trials, and that "half dose" thing.
https://mobile.reuters.com/article/amp/idUSKBN28Y0XU?__twitter_impression=true
Basically says that before AZ stepped in as partners, the Oxford team didn't really have the experience to ramp up from lab scale production to full clinical trial production. As a result they used the wrong test methodology to analyse the first batch of manufactured product (coming from an Italian sub-contractor).
AKA - the manufacturer knew how to test what it was manufacturing, the research team didn't.
Looks like AZ are trying to pick up the PR pieces, as well as running/rerunning the trials now. It would be great news if they have managed to get enough data from their global (AZ standardised) trials to produce some convincing trials results.
"Personally, I can say that I think their vaccine is much better than their communication," said Guido Rasi, who until last month was executive director of the European Medicines Agency, the European Union's regulator. He said the agency eventually will evaluate the trial data.
Says they retested the half dose full dose regimen. How come we’ve not seen news of this elsewhere at all..
IINM, after the half dose, full dose fiasco came to light, they already said they would retest it to get confirmationA bit suspicious that literally nobody else seems to have this
That is fantastic newsSays they retested the half dose full dose regimen. How come we’ve not seen news of this elsewhere at all..
Seriously, if this was a Russian or Chinese vaccine, we wouldn't be touching it with a barge pole.I hope this article isn't true. If this is really all the AZ boss has to go on when he told The Times about finding the sweet spot, then I truly hate their PR department:
https://www.livemint.com/science/he...11609181643451.html?__twitter_impression=true
That's basically suggesting that another cut of the trial group into another thin slice (those who got the second dose between two and three months of the first) gives them their new results. I don't like the methodology, nor do I like the implication - 3 months? That's a hell of a long time unless there is significant protection after the first.
I honestly prefer the straightforward, "60% is better than nothing," approach. Particularly as AZ haven't told us what efficacy they get after a single dose.
I'm hoping that we see something cleaner in the actual data that gets released (this week?). Any other claims should be the basis for ongoing trials, not for some kind of sales pitch. If having a safe, ready to rollout product at 60%, is going to save lives then that's the story that needs telling.
I have no issue with the 60%, which is also great.Seriously, if this was a Russian or Chinese vaccine, we wouldn't be touching it with a barge pole.
I'm all for doing sub-sets of groups where we test it at different doses and intervals to see if there is some optimisation, but they need to be separate studies and not "serendipity".
The vaccine is 60% effective at the strength they have tested properly.
I hope this article isn't true. If this is really all the AZ boss has to go on when he told The Times about finding the sweet spot, then I truly hate their PR department:
https://www.livemint.com/science/he...11609181643451.html?__twitter_impression=true
That's basically suggesting that another cut of the trial group into another thin slice (those who got the second dose between two and three months of the first) gives them their new results. I don't like the methodology, nor do I like the implication - 3 months? That's a hell of a long time unless there is significant protection after the first.
I honestly prefer the straightforward, "60% is better than nothing," approach. Particularly as AZ haven't told us what efficacy they get after a single dose.
I'm hoping that we see something cleaner in the actual data that gets released (this week?). Any other claims should be the basis for ongoing trials, not for some kind of sales pitch. If having a safe, ready to rollout product at 60%, is going to save lives then that's the story that needs telling.
Which would be worrying to have large swathes of the population unprotected for 3 months after dose 1.
Seriously, if this was a Russian or Chinese vaccine, we wouldn't be touching it with a barge pole.
I'm all for doing sub-sets of groups where we test it at different doses and intervals to see if there is some optimisation, but they need to be separate studies and not "serendipity".
The vaccine is 60% effective at the strength they have tested properly.
Astrazeneca approved!
Good news right?
Immunity will start to build from the moment you get the first dose. We don't know the details but I think we can be confident that it is far from being unprotected.